Streamline Health Solutions (STRM) Q1 2025 earnings summary

Executive summary

• Pro forma SaaS revenue grew 22% year-over-year in Q1 2024, excluding a non-renewed client, driven by product enhancements and new client wins.

• Net loss for Q1 2024 was $2.7 million, slightly improved from a $2.9 million loss in Q1 2023, reflecting cost savings from strategic restructuring.

• Booked SaaS ACV reached $15.9 million as of June 11, 2024, with $13.1 million implemented as of the call date.

• Strategic restructuring in late 2023 reduced workforce by 24%, with $5.8 million in expected annualized cost savings.

• Focus areas include product innovation, AI-driven automation, and expanding client relationships through partnerships and cross-selling.

Financial highlights

• Total Q1 2024 revenue was $4.3 million, down from $5.3 million in Q1 2023, primarily due to client non-renewals, partially offset by new SaaS contracts.

• SaaS revenue was $2.7 million (63% of total), compared to $3.2 million (60%) in Q1 2023; on a pro forma basis, SaaS revenue grew 22% year-over-year excluding a non-renewed contract.

• Adjusted EBITDA loss improved to $0.7 million from $1.3 million in Q1 2023; margin improved to (16)% from (25)% year-over-year.

• Operating expenses decreased 21% year-over-year, reflecting cost controls and restructuring.

• Cash and cash equivalents increased to $4.0 million as of April 30, 2024, from $3.2 million at January 31, 2024.

Outlook and guidance

• Management expects to achieve Adjusted EBITDA break-even run rate in the second half of 2024, targeting a $15.5 million SaaS run rate.

• Sequential revenue growth is expected in each quarter of fiscal 2024 as lost client revenue is replenished.

• Maintenance and support revenue is expected to decline further due to contract non-renewals and limited new sales.

• Cost savings from restructuring are expected to support margin improvement.